BlackRock Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

BlackRock Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1	Closed	-$16K	–	3784
2015 Q4	$16K	Hold	1	–	–	﹤0.01%	3542
2015 Q3	$15K	Hold	1	–	–	﹤0.01%	3579
2015 Q2	$21K	Buy	+1	New	+$13.9K	﹤0.01%	3498
2014 Q4	–	Sell	-1	Closed	-$8K	–	3712
2014 Q3	$8K	Buy	+1	New	+$10.9K	﹤0.01%	3598

Other funds holding GLMD

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

SKK

Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

CapWealth Advisors Franklin, Tennessee $1.46B AUM 33.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAD

Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return

BlackRock Advisors's GLMD Position: Q1 2016 in Review

BlackRock Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q1 2016, closing a stake of 1 share — an estimated $16K sold.

BlackRock Advisors first reported a position in GLMD in Q3 2014 and held it in 4 quarters. The position peaked at $21K in Q2 2015. 15 funds tracked by Wall St. Rank hold GLMD as of Q1 2016.

BlackRock Advisors reported no remaining Galmed Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
BlackRock Advisors sold 1 Galmed Pharmaceuticals share in Q1 2016, an estimated $16K.
BlackRock Advisors first reported a position in Galmed Pharmaceuticals in Q3 2014 and held it in 4 quarters.
BlackRock Advisors's Galmed Pharmaceuticals position peaked at $21K in Q2 2015.
15 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2016.

Based on BlackRock Advisors's 13F filing for Q1 2016, filed 10 May 2016.